天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 578-66-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 578-66-5
Chemical Structure| 578-66-5
Structure of 578-66-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 578-66-5 ]

Related Doc. of [ 578-66-5 ]

Alternatived Products of [ 578-66-5 ]
Product Citations

Product Citations      Expand+

Meiss, Cade J ; Bothwell, Paige J ; Webb, Michael I DOI:

Abstract: Recent recognition of the soluble form of the amyloid-beta (Ab) peptide as a neurotoxic agent in Alzheimer’sdis ease (AD) has spurred the development of agents to target this species. Because Ab is known to chelate metal ions in solu tion, metal-based therapeutics are uniquely suited to exploit this affinity, where coordination to Ab has been shown to impact the neurotoxicity of the peptide. Ruthenium(II)–arene complexes are unique candidates for evaluation, as one face ofthemoleculeisblockedbythehydrophobicarenering,whilecoordinationtotheAb peptide can occur on the other side of the molecule. We have prepared and evaluated two Ru(II)–arene complexes with chelating quinoline-based ligands, Ru1 and Ru2, for their respective anti-amyloid abilities. Although both complexes decreased the aggregation of soluble Ab, Ru1 displayed promise in disrupting formed aggregates of the peptide. These findings represent an exciting new avenue for therapeutic development in AD, where both sides of the aggregation equilibrium are affected.

Keywords: Alzheimer’s disease ; amyloid-beta ; ruthenium(II) therapeutics ; peptide aggregation

Purchased from AmBeed:

Jang, Mingyeong ; Lim, Taeho ; Park, Byoung Yong , et al. DOI: PubMed ID:

Abstract: In this study, we developed a metal-free and highly chemoselective method for the reduction of aromatic nitro compounds. This reduction was performed using tetrahydroxydiboron [B2(OH)4] as the reductant and 4,4'-bipyridine as the organocatalyst and could be completed within 5 min at room temperature. Under optimal conditions, nitroarenes with sensitive functional groups, such as vinyl, ethynyl, carbonyl, and halogen, were converted into the corresponding anilines with excellent selectivity while avoiding the undesirable reduction of the sensitive functional groups.

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Product Details of [ 578-66-5 ]

CAS No. :578-66-5 MDL No. :MFCD00006809
Formula : C9H8N2 Boiling Point : -
Linear Structure Formula :- InChI Key :WREVVZMUNPAPOV-UHFFFAOYSA-N
M.W : 144.17 Pubchem ID :11359
Synonyms :

Calculated chemistry of [ 578-66-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 46.15
TPSA : 38.91 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.91 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.45
Log Po/w (XLOGP3) : 1.79
Log Po/w (WLOGP) : 1.82
Log Po/w (MLOGP) : 1.19
Log Po/w (SILICOS-IT) : 1.77
Consensus Log Po/w : 1.61

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.53
Solubility : 0.421 mg/ml ; 0.00292 mol/l
Class : Soluble
Log S (Ali) : -2.23
Solubility : 0.857 mg/ml ; 0.00595 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.32
Solubility : 0.0693 mg/ml ; 0.000481 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.09

Safety of [ 578-66-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 578-66-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 578-66-5 ]

[ 578-66-5 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 578-66-5 ]
  • [ 89694-46-2 ]
  • [ 1644565-60-5 ]
  • 2
  • [ 40915-37-5 ]
  • [ 578-66-5 ]
  • [ 1428858-71-2 ]
  • 3
  • [ 40915-37-5 ]
  • [ 578-66-5 ]
  • 7,8-dipropyl-1-(quinolin-8-yl)-4,5-dihydro-2H-pyrano[3,2-c]pyridin-2(1H)-one [ No CAS ]
  • 4
  • [ 578-66-5 ]
  • [ 13612-34-5 ]
  • 2-(2,5-dimethylphenyl)-N-(quinolin-8-yl)acetamide [ No CAS ]
  • 5
  • [ 578-66-5 ]
  • [ 23872-36-8 ]
  • C18H12ClN3O [ No CAS ]
  • 6
  • [ 578-66-5 ]
  • [ 10241-97-1 ]
  • C19H15N3O [ No CAS ]
  • 7
  • [ 578-66-5 ]
  • [ 54221-96-4 ]
  • (E)-8-quinoline-N-((6-methoxypyridin-2-yl)methylene)amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
85% In methanol; for 2.5h;Reflux; 6-Methoxy-2-pyridinecarboxaldehyde (0.65 mL, 5.40 mmol) and 8-aminoquinoline (0.77 g,5.37 mmol) were dissolved in 25 mL of anhydrous methanol and the resulting mixture was heated at reflux temperature for 2.5 h. The solvent was removed under reduced pressure togive brown solids. Yield: 1.20 g (85percent). Anal. Calcd (percent) for C16H13N3O (M = 263.30 g mol?1): C,72.99; H, 4.98; N, 15.96. Found: C, 72.85; H, 4.90; N, 15.97. FT-IR (KBr, cm?1): 3444(w), 3040(w),2948(w), 2822(w), 1651(m), 1599(s), 1576(s), 1517(s), 1470(s), 1440(m), 1415(m), 1379(m),1335(m), 1291(m), 1264(m), 1234(w), 1215(w), 1189(w), 1148(m), 1058(m), 1033(s), 990(m),894(w), 820(s), 791(s), 746(m), 643(w), 578(w), 524(w), 513(w), 747(w), 455(w). 1H NMR(400 MHz, CDCl3): delta 9.00 (s, 1H, Quinolone-H2), 8.79 (s, 1H, CH = N), 7.38?8.08 (m, 5H,Quinolone-H3,4,5,6,7), 6.95?7.19 (m, 3H, Py-H3,4,5), 4.05 (s, 3H, -OCH3) ppm.
  • 8
  • [ 578-66-5 ]
  • [ 430-99-9 ]
  • C12H9FN2O [ No CAS ]
  • 9
  • [ 578-66-5 ]
  • [ 6624-49-3 ]
  • N-8-quinolyl-3-isoquinolinecarboxamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
76% With pyridine; triphenyl phosphite; at 110℃; for 4h;Inert atmosphere; Schlenk technique; General procedure: The ligands were synthesized according to published methods withminor modifications [26-28]. To a solution of either 8-aminoquinolineor picolinamide (5.00×10-3 mol) in 10 mL dry pyridine was added asolution of the corresponding picolinic acid or 1-isoquinolinecarboxylicacid or <strong>[6624-49-3]3-isoquinolinecarboxylic acid</strong> (5.00×10-3 mol) in 10 mL. Themixture was stirred, heated to 110 C and triphenylphosphite(5.00×10-3 mol) was added drop-wise. The resulting brown solutionwas refluxed for 4 h.
  • 10
  • [ 578-66-5 ]
  • [ 6624-49-3 ]
  • N-(8-quinolyl)-3-isoquinolinecarboxamideplatinum(II) chloride [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 578-66-5 ]

Amines

Chemical Structure| 18978-78-4

[ 18978-78-4 ]

2-Methylquinolin-8-amine

Similarity: 0.94

Chemical Structure| 580-15-4

[ 580-15-4 ]

6-Aminoquinoline

Similarity: 0.92

Chemical Structure| 611-34-7

[ 611-34-7 ]

Quinolin-5-amine

Similarity: 0.88

Chemical Structure| 578-68-7

[ 578-68-7 ]

4-Aminoquinoline

Similarity: 0.88

Chemical Structure| 1246556-01-3

[ 1246556-01-3 ]

Quinolin-7-amine hydrochloride

Similarity: 0.88

Related Parent Nucleus of
[ 578-66-5 ]

Quinolines

Chemical Structure| 18978-78-4

[ 18978-78-4 ]

2-Methylquinolin-8-amine

Similarity: 0.94

Chemical Structure| 580-15-4

[ 580-15-4 ]

6-Aminoquinoline

Similarity: 0.92

Chemical Structure| 129844-69-5

[ 129844-69-5 ]

6-Methylquinolin-7-amine

Similarity: 0.88

Chemical Structure| 611-34-7

[ 611-34-7 ]

Quinolin-5-amine

Similarity: 0.88

Chemical Structure| 578-68-7

[ 578-68-7 ]

4-Aminoquinoline

Similarity: 0.88

; ;